Key clinical point: Entospletinib has limited activity against relapsed/refractory diffuse large B-cell lymphoma and a high rate of adverse events.
Major finding: The rate of progression-free survival at 16 weeks was 3.6% with a median PFS of 1.5 months.
Study details: An analysis of 43 relapsed/refractory DLBCL patients who received single-agent entospletinib.
Disclosures: The study was supported by Gilead Sciences. Dr. Burke reported relationships with Gilead and other companies.
Burke JM et al. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):e327-e331.
This Week's Must Reads
Must Reads in Aggressive Lymphomas
Researchers characterize new subtype of high-grade DLBCL, 3 articles from the Journal of Clinical Oncology